Roche eyes an uncertain market for faricimab

You come at the king, you best not miss. And, to be fair, Roche’s faricimab did not miss exactly in its two head-to-head trials versus the leading diabetic macular oedema therapy, Regeneron’s Eylea. But neither did it land a knockout blow.